Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
new formulations of 611 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Tested preparation group | EXPERIMENTAL | Healthy subjects will receive new formulations of 611 300mg once |
| Reference preparation group | EXPERIMENTAL | Healthy subjects will receive existing formulations of 611 300mg once |
| Name | Type | Description |
|---|---|---|
| new formulations of 611 | DRUG | Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1 |
| existing formulations of 611 | DRUG | Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1 |
Inclusion Criteria: 1. Willingness to provide written informed consent for the study. 2. Male or female subjects, age 18-45 years older. 3. Within body mass index (BMI) range 19.0 to 26.0 kilograms per square meter (kg/m²). 4. The results of vital signs, physical examination, laboratory tests, elec...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
611 is an investigational small molecule being developed for the treatment of Atopic Dermatitis. It is currently in Phase 1 clinical development, with a study planned in healthy adult subjects in China. The drug is not yet approved and remains under investigation for this dermatological condition.
611 is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM. The company is conducting clinical trials for this investigational drug, which is currently in Phase 1 development for Atopic Dermatitis.
611 is in Phase 1 clinical development. A Phase 1 study, NCT07042113, is planned but not yet recruiting participants. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of Atopic Dermatitis.
611 is associated with one clinical trial, NCT07042113, titled 'A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China'. This Phase 1 study is not yet recruiting and aims to enroll 180 participants. The trial is controlled and randomized, though not double-blind.
611 is being studied in two different formulations, as indicated by the clinical trial NCT07042113, which evaluates both versions in healthy adults. These formulations are part of the same investigational drug program for Atopic Dermatitis, but specific alternative names have not been disclosed.